101 related articles for article (PubMed ID: 1949386)
21. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
Samodai L; Dankó K
Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
[TBL] [Abstract][Full Text] [Related]
22. Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette Guerin and systemic interleukin 2.
Lee KE; Weiss GH; O'Donnell RW; Cockett AT
J Urol; 1987 Jun; 137(6):1270-3. PubMed ID: 3495671
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells.
Ratliff TL; Shapiro A; Catalona WJ
Clin Immunol Immunopathol; 1986 Oct; 41(1):108-15. PubMed ID: 3527506
[TBL] [Abstract][Full Text] [Related]
24. Monocyte-mediated cytotoxicity on bladder cancer cells in vitro and its implication in the treatment of bladder cancer patients with bacillus Calmette-Guérin.
Nakamura K
Keio J Med; 1984 Nov; 33(4):185-99. PubMed ID: 6530875
[No Abstract] [Full Text] [Related]
25. On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells.
Böhle A; Thanhäuser A; Ulmer AJ; Mattern T; Ernst M; Flad HD; Jocham D
Urol Res; 1994; 22(3):185-90. PubMed ID: 7527607
[TBL] [Abstract][Full Text] [Related]
26. Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
Jpn J Cancer Res; 2000 May; 91(5):534-42. PubMed ID: 10835499
[TBL] [Abstract][Full Text] [Related]
27. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
29. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
30. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
31. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
32. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
[TBL] [Abstract][Full Text] [Related]
33. Natural killer cell activity in patients with prostatic carcinoma and its in vivo boosting with bacillus Calmette-Guérin.
Schwemmer B; Lehmer A; Hofmann R; Braun J
Urol Int; 1984; 39(6):321-6. PubMed ID: 6523641
[TBL] [Abstract][Full Text] [Related]
34. Natural Killer Anti-Tumor Activity Can Be Achieved by
Esteso G; Aguiló N; Julián E; Ashiru O; Ho MM; Martín C; Valés-Gómez M
Front Immunol; 2021; 12():622995. PubMed ID: 33708215
[TBL] [Abstract][Full Text] [Related]
35. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
36. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
37. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
38. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
39. Towards an understanding of the mode of action of Bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin.
van der Sloot E; Kuster S; Böhle A; Braun J; Wood WG
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):503-11. PubMed ID: 1333824
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity.
Cheng DL; Shu WP; Choi JC; Margolis EJ; Droller MJ; Liu BC
J Urol; 1994 Oct; 152(4):1275-80. PubMed ID: 8072119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
